Pseudoprogression in patients with glioblastoma: Clinical relevance despite low incidence

Neuro-Oncology

Volumn 17, Issue 1, 2015, Pages 151-159

  Radbruch, Alexander ^a,b   Fladt, Joachim ^a   Kickingereder, Philipp ^a   Wiestler, Benedikt ^a,b   Nowosielski, Martha ^c   Baümer, Philipp ^a   Schlemmer, Heinz Peter ^b   Wick, Antje ^a,b   Heiland, Sabine ^a   Wick, Wolfgang ^a,b   Bendszus, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Glioblastoma; Pseudoprogression

Indexed keywords

STEROID; CONTRAST MEDIUM;

ADULT; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER SURGERY; CHEMORADIOTHERAPY; CONTRAST ENHANCEMENT; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PSEUDOPROGRESSION; RETROSPECTIVE STUDY; STEROID THERAPY; BRAIN NEOPLASMS; DISEASE COURSE; INCIDENCE; KAPLAN MEIER METHOD; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; BRAIN NEOPLASMS; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDIES;

EID: 84922530499     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou129     Document Type: Article

References (27)

1. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
2. Gerstner ER, McNamara MB, Norden AD, et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009;94(1):97-101.
3. Lee WJ, Choi SH, Park CK, et al. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. Acad Radiol. 2012;19(11):1353-1361.
4. Sundgren PC, Fan X, Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging. 2006;24(9):1131-1142.
5. Sundgren PC. MR spectroscopy in radiation injury. AJNR Am J Neuroradiol. 2009;30(8):1469-1476.
6. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrastenhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys. 2011; 79(2):514-523.
7. Suh CH, Kim HS, Choi YJ, et al. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging. AJNR Am J Neuroradiol. 2013;34(12):2278-2286.
8. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978-1985.
9. Shah AH, Snelling B, Bregy A, et al. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review. What is the best imaging modality? J Neurooncol. 2013; 112(2):141-152.
10. Verma N, Cowperthwaite MC, Burnett MG, et al. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol. 2013;15(5): 515-534.
11. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
12. Tran DK, Jensen RL. Treatment-related brain tumor imaging changes: so-called pseudoprogression vs. tumor progression: review and future research opportunities. Surg Neurol Int. 2013; 4(Suppl 3):S129-S135.
13. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
14. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13):2192-2197.
15. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-461.
16. Chaskis C, Neyns B, Michotte A, et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. 2009;72(4):423-428.
17. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27(8): 1275-1279.
18. Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. 2010;256(2):575-584.
19. Sanghera P, Perry J, Sahgal A, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci. 2010;37(1):36-42.
20. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113(2):405-410.
21. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
22. Stuplich M, Hadizadeh DR, Kuchelmeister K, et al. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. J Clin Oncol. 2012;30(21): e180-e183.
23. Fink J, Born D, Chamberlain MC. Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol. 2011;12(3):240-252.
24. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol. 2006;111(3):197-212.
25. PopeWB, Hessel C. Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials. AJNR Am J Neuroradiol. 2011;32(5):794-797.
26. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82(1):81-83.
27. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22(6):633-638.